Pfizer CEO flags concerns with US FDA's vaccine leadership

By Mariam Sunny March 2 (Reuters) - Pfizer CEO Albert Bourla said the company "has a problem" with the U.S. Food and Drug Administration's biologics and vaccines chief, Vinay Prasad, in response to a ...
Becker's Hospital Review

Pfizer gets FDA priority review for pediatric hemophilia treatment

Pfizer has received FDA priority review for a supplemental biologics license application to expand the indication of Hympavzi (marstacimab). The proposed label expansion would include patients with ...
Seeking Alpha

Pfizer wins FDA priority review for Hympavzi label expansion

Pfizer (PFE) announced on Friday that the U.S. Food and Drug Administration granted priority review for a marketing application seeking a label expansion for its hemophilia therapy, Hympavzi. The New ...
Nasdaq

Pfizer Gets FDA Priority Review For Expanded Use Of HYMPAVZI

(RTTNews) - Pfizer Inc. (PFE) on Friday said the U.S. Food and Drug Administration (FDA) has granted Priority Review to the company's supplemental Biologics License Application (sBLA) for HYMPAVZI.

Pfizer CEO flags issues with FDA's vaccine leadership

Pfizer CEO Albert Bourla said the company "has a problem" with the U.S. Food and Drug Administration's biologics and vaccines chief, Vinay Prasad.
Morningstar

Pfizer Gets FDA Priority Review for Expanded Hympavzi Approval

Pfizer has won U.S. Food and Drug Administration priority review for its application seeking expanded approval of its Hympavzi hemophilia drug for two patient populations with significant medical need ...